Publications by authors named "Haobin Deng"

Claim this Profile
B
Biomaterial-driven regenerative drug delivery: a vicennial bibliometric landscape.
Xin Shen, Haobin Deng, Jing Lin, Jianhua Wang, Yilun Liu

Front Med (Lausanne)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Visualized trends and bibliometric analysis in ankle cartilage repair from 2004 to 2024.
Xuefei Fu, Zhixing Zhang, Yingxiang Wang, Lin Lu, Tao Chen, Haobin Deng

Front Med (Lausanne)· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Osteoarthritis with depression: mapping publication status and exploring hotspots.
Meng Zhang, Hao Li, Qingshan Li, Zhen Yang, Haobin Deng

Front Psychol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Research hotspots and trends of mesenchymal stem cell-derived extracellular vesicles for drug delivery: a bibliometric and visualization analysis from 2013 to 2023.
Tianyuan Zhao, Yuhao Mu, Haobin Deng, Kaini Liang, Fanfan Zhou

Front Cell Dev Biol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical application of V-shaped folded submental flap in the repair of oral defect.
Ruohuang Lu, Haobin Deng, Xincheng Guo, Jie Dai, Pingping Gan

Zhong Nan Da Xue Xue Bao Yi Xue Ban· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global cluster analysis and network visualization in organoids in cancer research: a scientometric mapping from 1991 to 2021.
Shunshun Tan, Jiali Deng, Haobin Deng, Lijun Lu, Zhenzhe Qin

Front Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of the quadrivalent inactivated split-virion influenza vaccine in populations aged ≥ 3 years: A phase 3, randomized, double-blind, non-inferiority clinical trial.
Jianmin Chen, Feng Jiang, Chenyan Zhao, Jing Chai, Lanshu Li, Haobin Deng

Hum Vaccin Immunother· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of programmed cell death 1 inhibitor maintenance therapy after combined treatment with programmed cell death 1 inhibitors and anti-CD19-chimeric antigen receptor T cells in patients with relapsed/refractory diffuse large B-cell lymphoma and high tumor burden.
Juan Mu, Haobin Deng, Cuicui Lyu, Jijun Yuan, Qing Li, Qi Deng

Hematol Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.
Haobin Deng, Meijing Liu, Ting Yuan, Huan Zhang, Rui Cui, Qi Deng

Front Immunol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
Meijing Liu, Haobin Deng, Juan Mu, Qing Li, Yedi Pu, Qi Deng

Cancer Sci· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-CD22 CAR-T Cell Therapy as a Salvage Treatment in B Cell Malignancies Refractory or Relapsed After Anti-CD19 CAR-T therapy.
Haibo Zhu, Haobin Deng, Juan Mu, Cuicui Lyu, Yanyu Jiang, Qi Deng

Onco Targets Ther· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis